Previous 10 | Next 10 |
The last few weeks have seen a lot of buyout chatter on AUPH. The CEO made some interesting comments in this regard in their earnings call. I believe the recent drop in price may be an opportunity. For further details see: Aurinia Buyout Chatter: CEO Says To 'Read Betwee...
Aurinia won approval for Lupus Nephritis therapy LUPKYNIS in January this year, causing its share price to reach a high of $19. Analysts believe the drug can achieve >$1bn per annum sales, and longer term, $2bn may not be unrealistic. That has created a slew of recent M&A r...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aurinia Pharma (NASDAQ: AUPH ) stock is taking a beating on Monday following a filing with the U.S. Securities and Exchange Commission (SEC) on Friday. Source: Bukhta Yurii / Shutterstock.com Let’s jump...
Shares of Aurinia Pharmaceuticals (AUPH -28.8%) are down 28% today after filing for a mixed shelf offering late Friday. The offering is for common shares, debt securities, and warrants. Some investors see the offering as sign that a potential buyout of Aurinia may not happen. Last m...
Gainers: iSpecimen (NASDAQ:ISPC) +85%. Navitas Semiconductor (NYSE:NVTSW) +29%. Vonage (NASDAQ:VG) +26%. Astra (NASDAQ:ASTR) +25%. Avaya (NYSE:AVYA) +25%. Lee Enterprises (NASDAQ:LEE) +24%. Cloopen Group (NYSE:RAAS) +24%. MultiPlan (NYSE:MPLN) +23%. Partner (NASDAQ:PTNR) +20%. Camber Energy (...
Aurinia Pharmaceuticals (NASDAQ: AUPH) stock has fallen sharply in response to a recent regulatory filing. Investors feeling queasy about the unlimited shelf registration statement that the company filed on Friday had pulled its share price down by 26.8% as of 10:49 a.m. ET Monday. ...
Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...
Aurinia Pharmaceuticals (NASDAQ:AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in after-hours trading. Aurinia said it plans to use proceeds for clinical development and c...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021. The presentation will be available to all conference attendees...
Bristol Myers Squibb (NYSE: BMY) is reportedly interested in acquiring Aurina Pharmaceuticals (NASDAQ: AUPH) . In this Motley Fool Live video recorded on Oct. 27 , Fool contributors Keith Speights and Brian Orelli discuss whether this deal would be a smart move ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...